|
|
|
Info: Your browser does not accept cookies. If you want to put products into your cart and purchase them you need to enable cookies.
Browse
Pipeline/Commercial Insight: Antihypertensives
Analysis of the antihypertensives pipeline and the competitive landscape across seven major markets. Analysis of the threats to currently marketed drugs. Assessment of the opportunity available to novel agents, including Novartis’s Tekturna.
Commercial and Pipeline Insight: ADHD
This report provides full analysis of the current and future ADHD market, with sales forecasts to 2017 of marketed brands, generics, and key pipeline drugs in the US, 5EU, and Japan, as well as insight from key opinion leaders.
Pipeline and Commercial Insight: Schizophrenia
This report provides full analysis of the current and future schizophrenia drug market, with indication-specific sales value and volume forecasts to 2017 of branded, generic, and key pipeline drugs in the US, Japan, and five major European markets.
Commercial and Pipeline Insight: Opioids
This report provides full analysis of the current and future Opioid market, with indication-specific sales forecasts to 2017 of marketed brands, generics, and key pipeline drugs in the US, 5EU, and Japan.
Pipeline and Commercial Insight: Neuropathic Pain
This report provides full analysis of the current and future neuropathic pain market, with indication-specific sales forecasts to 2017 of marketed brands, generics, and key pipeline drugs in the US, 5EU, and Japan.
Pipeline and Commercial Insight: Alzheimers Disease
This report provides full analysis of the future Alzheimer’s disease (AD) market, with four indication- and region-specific scenario forecasts evaluating the commercial potential of pipeline and marketed drugs.
Commercial and Pipeline Insight: Fibromyalgia
This report provides full analysis of the current and future fibromyalgia market, with indication-specific forecasts to 2017 of branded, generic, and key pipeline drugs in the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK).<
Pipeline and Commercial Insight: Urinary Incontinence
The UI market is set to continue to grow over the next 6 years, reaching over $2.5 billion in 2012, a 68% increase from 2006. Lifecycle management strategies, novel formulations and follow-on products will drive the majority of this growth, with key b
Results 1 - 10 of 10
|
|
|
|
